Medial cavernous sinus wall resection achieves 85% endocrine remission in functioning pituitary adenomasSurgery Technique Shows High Success for Pituitary Tumor Treatment

Neurosurgical review Published September 18, 2026 Study authors: Vargas Luis O, Himic Vratko, Kazimli Vagif, Cummings Adonicah, Kreatsoulas Daniel, Jahangiri Arman, … PubMed ↗ DOI ↗ Editorial oversight: Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Note that MCSWR is associated with high remission rates but evidence is limited by high risk of bias.

This meta-analysis evaluates the efficacy and safety of medial cavernous sinus wall resection (MCSWR) for patients with functioning pituitary adenomas, including acromegaly, Cushing's disease, and prolactinomas. The analysis included 493 patients with follow-up periods ranging from 9 to 30 months. The primary finding was an endocrine remission (ER) rate of 85% (95% CI: 77-91%) and a gross total resection (GTR) rate of 92% (95% CI: 81-97%).

Specific outcomes for acromegaly showed an ER rate of 87% and a GTR rate of 95%. For Cushing's disease, the ER rate was 89% and the GTR rate was 91%. For prolactinomas, the ER rate was 78% and the GTR rate was 80%. The recurrence rate was reported as 6% (95% CI: 3-13%). Safety data indicated 0% ICA injury, 3% each for cranial nerve III and VI palsies, and a 4% postoperative CSF leak rate.

The authors note significant limitations, including a high risk of bias in most studies, confounding, and the use of single-arm, non-comparative designs. Furthermore, some series had limited follow-up. Due to these factors, the evidence for MCSWR is currently considered of limited certainty. Clinical application should be weighed against the lack of prospective, multicenter data.

How this fits prior evidence

This meta-analysis extends the existing evidence regarding surgical options for Cushing's disease. While prior coverage noted a 73.88% remission rate for transsphenoidal surgery in Cushing's disease, this meta-analysis reports a higher 89% endocrine remission rate specifically for Cushing's disease following MCSWR. However, the current finding is based on non-comparative series and high risk of bias, which may affect the reliability of the higher reported remission rate compared to previous transsphenoidal surgery data.

Researchers analyzed data from 493 adults with functioning pituitary adenomas, including conditions like acromegaly, Cushing's disease, and prolactinoma. The study looked at a specific surgical technique called medial cavernous sinus wall resection (MCSWR) to see how well it worked for these patients.

The results showed that 85% of patients achieved endocrine remission. The surgery also resulted in a gross total resection of the tumor in 92% of cases. For specific conditions, the remission rates were 87% for acromegaly and 89% for Cushing's disease. The study also noted a low recurrence rate of 6%.

While the results are promising, the evidence is limited because many of the original studies were not designed to compare different treatments. Some studies were small or had a high risk of bias. Patients should talk to their doctors to see if this specific surgical approach is appropriate for their unique medical situation.

What this means for you:

MCSWR shows high remission rates for pituitary tumors, but evidence is limited by study design and bias.

Common questions

What is the success rate for this surgery?

The study found that 85% of patients achieved endocrine remission after the procedure. Additionally, 92% of patients had a gross total resection of their tumor. These figures suggest the technique is effective for many patients with acromegaly, Cushing's disease, and prolactinoma.

Are there any risks or side effects associated with MCSWR?

The study reported some specific risks: 0% internal carotid artery injury, 3% each for cranial nerve III and VI palsies, and a 4% rate of postoperative CSF leak. These results suggest the procedure has an acceptable level of morbidity for many patients.

How often does the condition return after surgery?

The data showed a low recurrence rate of 6% for patients who underwent the procedure. However, because the evidence comes from non-comparative series, you should discuss the long-term outlook with your doctor.

Study Details

Study typeMeta analysis

Sample sizen = 493

EvidenceLevel 1

Follow-up30.0 mo

PublishedSep 2026

PMID42753014

View Original Abstract ↓

Functioning pituitary adenomas (FPAs) require both cytoreduction and durable endocrinological remission (ER), which is often limited by occult invasion of the medial cavernous sinus wall. Selective medial cavernous sinus wall resection (MCSWR) has emerged as a targeted approach, but its endocrine benefits and safety profile remain incompletely understood. We synthesize syndrome-specific remission, resection, recurrence, and complication rates after MCSWR in adults with FPAs. We conducted a systematic review and meta-analysis of PubMed, Scopus, and Embase through 2025, including adults with GH-, ACTH-, and prolactin-secreting adenomas who underwent intentional medial cavernous sinus wall resection as described by the original studies and had at least one postoperative endocrine outcome. Two reviewers extracted study- and tumor-level data on resection, ER, recurrence, and complications. Pooled event rates were estimated with random-effects models. Thirteen studies (11 retrospective, 2 prospective) involving 493 patients met inclusion criteria. Among 344 patients with available endocrine follow-up, pooled ER was 85% (95% CI:77-91%), and gross total resection (GTR) was 92% (95% CI:81-97%). Recurrence occurred in 6% (95% CI:3-13%). Subgroup ER rates were 87% for acromegaly, 89% for Cushing's disease, and 78% for prolactinomas, with corresponding GTR rates of 95%, 91%, and 80%. Complications were rare: ICA injury 0%, cranial nerve III and VI palsies 3% each, and postoperative CSF leak 4%. Most studies had a serious or critical risk of bias, mainly due to confounding and single-arm designs. Follow-up ranged from 9 to 30 months in contributing cohorts, with earlier series reporting ranges up to 1-49 months. MCSWR was associated with high reported ER and GTR rates, low reported recurrence, and acceptable morbidity in carefully selected patients with FPAs, particularly somatotroph and corticotroph tumors. However, the evidence mainly comes from high-volume centers and non-comparative series with limited follow-up, highlighting the need for prospective, multicenter studies with standardized endocrine endpoints, histological confirmation, and long-term follow-up.

Medial cavernous sinus wall resection achieves 85% endocrine remission in functioning pituitary adenomasSurgery Technique Shows High Success for Pituitary Tumor Treatment

How this fits prior evidence

Common questions

Study Details

First-line immune checkpoint inhibitor combinations improve overall survival in extensive-stage small-cell lung cancer

Immune checkpoint inhibitors combined with chemotherapy improve small cell lung cancer survival

Clinical research that matters. Delivered to your inbox.

Medial cavernous sinus wall resection achieves 85% endocrine remission in functioning pituitary adenomasSurgery Technique Shows High Success for Pituitary Tumor Treatment

How this fits prior evidence

Common questions

More on Cushing's Disease

Study Details

First-line immune checkpoint inhibitor combinations improve overall survival in extensive-stage small-cell lung cancer

Immune checkpoint inhibitors combined with chemotherapy improve small cell lung cancer survival

Clinical research that matters. Delivered to your inbox.

Related in Oncology

From Other Specialties